Business Overview: Pulmonx Corporation (Nasdaq: LUNG)

---

Executive Summary

Pulmonx is a medical device company that developed and commercializes the Zephyr Valve, a minimally invasive, bronchoscopically-placed endobronchial valve used to treat severe emphysema (a form of COPD) through endoscopic lung volume reduction — avoiding open surgery. The Zephyr Valve is sold in more than 25 countries. Q1 2025 worldwide revenue grew 20% to $22.5 million (73% gross margin), and the company reaffirmed FY2025 guidance of $96–$98 million in revenue at roughly 74% gross margin. Pulmonx remains unprofitable (Q1 net loss of $14.4 million) but holds a healthy cash position ($88.7 million) and an extended, interest-only CIBC loan through October 2027.

---

1. Core Business Model & How They Work

Severe Emphysema Patient Diagnosis ➡️ Pulmonologist/Interventional Specialist Evaluation
        ➡️ Chartis Diagnostic Assessment (collateral ventilation screening)
        ➡️ Bronchoscopic Zephyr Valve Placement (non-surgical)
        ➡️ Lung Volume Reduction ➡️ Improved Lung Function / Quality of Life
        ➡️ "Acquire, Test, and Treat" Strategy ➡️ Broader Hospital/Physician Adoption

Pulmonx sells capital diagnostic equipment (the Chartis system) alongside the disposable Zephyr Valve itself, creating a razor/razorblade-style revenue model: once a hospital adopts the diagnostic and procedural workflow, valve sales recur with each treated patient.

---

2. Business Segments

Pulmonx operates as a single reportable segment, geographically split:

                     Pulmonx Corporation
                             │
        ┌─────────────────────┼─────────────────────┐
        │                                              │
   U.S. Revenue                              International Revenue
   ($14.2M, Q1'25, +11%)                     ($8.3M, Q1'25, +39%)

International revenue is currently growing faster than the U.S., reflecting earlier-stage market penetration and expanding reimbursement/adoption outside the U.S.

---

3. Product Portfolio

---

4. Competitive Landscape

• Surgical lung volume reduction surgery (LVRS) — the older, more invasive standard-of-care alternative
• Coil-based bronchoscopic therapies (formerly PneumRx/BTG, now largely discontinued) — a historical, now largely retreated alternative device approach
• Broncus Medical — develops competing bronchoscopic intervention technologies in some international markets
• Pharmaceutical COPD/emphysema management — the much larger incumbent standard of care that Pulmonx must displace at the margin

Pulmonx's key competitive edge is being the clinically validated, broadly reimbursed, minimally invasive leader in bronchoscopic lung volume reduction, with few direct device competitors remaining active in the category.

---

5. Strategic Strengths & Risks

Strengths

• First-mover, category-defining position in bronchoscopic valve-based lung volume reduction with limited remaining direct device competition
• Strong, durable revenue growth (+20% in Q1 2025) and high gross margin (73–74%) typical of a differentiated medical device franchise
• Razor/razorblade model (Chartis diagnostic placement drives recurring Zephyr Valve procedure revenue)
• Adequate near-term liquidity ($88.7 million cash) and an extended interest-only loan period reduce near-term financing risk

Risks

• Still unprofitable at the operating level; scaling commercial infrastructure continues to outpace revenue growth
• Dependent on physician training and procedural adoption curves, which can be slow in a conservative medical specialty
• International growth, while strong, is more exposed to reimbursement-policy variability across markets
• A niche, single-product-platform company faces concentration risk if clinical, reimbursement, or competitive dynamics shift

---

6. Financial Overview

---

Summary Conclusion

Pulmonx occupies a differentiated, clinically validated niche in minimally invasive emphysema treatment with strong revenue growth and high gross margins, but it remains a sub-$100 million-revenue company still working toward sustained profitability. Its durable procedural/razor-blade model and limited direct device competition are the key supports for its long-term investment case.